Dentsply Sirona Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumables for urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. Founded in 1877, it is headquartered in Charlotte, North Carolina.
Dentsply Sirona: weak sales, but profit recovery and dealer expansion
▼
Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.
The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.
Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.
Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.
Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.
This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.
Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.
Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.
Dentsply Sirona Expands Midwest Dental Deal to Include Technology Portfolio
Dentsply Sirona announced an expanded relationship with Midwest Dental Equipment & Supply that will bring its technology portfolio to the independent distributor's customers in the United States starting November 1, 2026. The agreement builds on a relationship that had historically focused on consumables, and it increases access to Dentsply Sirona's digital dentistry solutions through Midwest Dental's network of sales, service, and technical specialists. The Midwest Dental deal marks Dentsply Sirona's seventh North American dealer partnership enhancement of 2026, following new technology agreements with Benco Dental Supply Co., The Burkhart Dental Supply Co., Nashville Dental, Inc., The Atlanta Dental Supply Company, and Medline Sinclair, as well as a renewed partnership with Patterson Dental. Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona, said Midwest Dental has built strong relationships across the markets it serves, making it an important partner as the company continues expanding access to connected dentistry. Midwest Dental Equipment & Supply, founded in 1988 and headquartered in Wichita Falls, Texas, is the largest independent, family-owned distributor in the Southern U.S., serving dental professionals nationwide with teams in Texas, Oklahoma, New Mexico, and Arkansas.
Aging Population › Hearing / Vision / Dental Supply
XRAY · Demand · Positive Expanded Midwest Dental deal brings Dentsply Sirona's technology portfolio to more US customers, increasing access and distribution of its digital dentistry products.
Dentsply Sirona Inc. reported second-quarter adjusted earnings of 52 cents per share, beating the Zacks Consensus Estimate of 36 cents by 44.4%, while revenues of $898 million topped expectations by 1.6%, despite a 4.1% year-over-year decline as reported and a 6.3% drop at constant currency. The company maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted earnings guidance of $1.40-$1.50 per share, excluding tariff refund benefits. Wellspect Healthcare was the bright spot, with revenues up 7.1% to $86 million, while Connected Technology Solutions fell 1.5%, Essential Dental Solutions declined 2.7%, and Orthodontic and Implant Solutions dropped 13.2%. Adjusted gross margin improved 50 basis points to 56.4%, and adjusted EBITDA margin rose 20 basis points to 21.3%, but adjusted operating margin contracted 240 basis points to 15.8% due to lower volumes, unfavorable mix, tariff costs, and higher expenses. Free cash flow increased to $55 million from $16 million a year earlier, though cash and equivalents fell to $239 million from $326 million at year-end 2025, with net debt-to-EBITDA at 3.2.
Dentsply Sirona Q2 Earnings Beat Estimates but Shares Fall
Dentsply Sirona reported second quarter revenue of $898 million, beating analyst estimates of $892.6 million, while adjusted EPS of $0.52 far exceeded the $0.35 consensus, yet shares declined following the announcement. The company reconfirmed full-year revenue guidance of $3.55 billion at the midpoint and reiterated adjusted EPS guidance of $1.45 at the midpoint. CEO Daniel Scavilla described the current phase as a turnaround, noting uneven improvement across segments and geographies, with lower sales volumes in the Americas and EMEA and ongoing challenges in capital equipment demand and distributor inventory reduction. During the earnings call, analysts questioned the timing of EPS improvement, the impact of tariff refunds on guidance, and the pace of U.S. commercial team productivity gains, with Scavilla indicating most benefits from recent hires and dealer additions will be realized in the fourth quarter and next year, and tariff refunds were not embedded in guidance.
XRAY · Capital · Negative Shares fell despite Q2 earnings beat and guidance reaffirmation, as analysts questioned timing of EPS improvement and tariff refunds not embedded in guidance.
Dentsply Sirona Q2 revenue falls 4.1% to $898 million
Dentsply Sirona reported second quarter 2026 revenue of $898 million, a 4.1% reported decline or 6.3% on a constant currency basis, while adjusted EPS was flat year over year at $0.52 including a $0.17 per share positive impact from tariff refunds. The company recorded a $44 million tariff refund in the quarter, which it used partially to fund opportunistic share repurchases of 1.3 million shares for approximately $12 million at an average price below $10 per share. Operating cash flow rose to $99 million from $48 million in the prior year quarter, driven by the tariff refund and improved management of accounts payable and inventory. Full-year revenue guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50 were maintained, excluding the benefit from tariff refunds and the impact of incremental tariffs. Management expects third quarter revenue to decline sequentially due to seasonality and earnings to be below second quarter levels excluding the tariff refund, with improvement weighted toward the fourth quarter.
Dentsply Sirona maintains 2026 outlook of $3.5B-$3.6B sales and $1.40-$1.50 adjusted EPS while ramping return-to-growth investments
Dentsply Sirona maintained its full-year 2026 guidance for net sales of $3.5 billion to $3.6 billion and adjusted earnings per share of $1.40 to $1.50, excluding tariff refunds and incremental tariffs. The company reported second-quarter revenue of $898 million and adjusted EPS of $0.52, which included a $0.17 per share benefit from $44 million in tariff refunds. Management expects third-quarter revenue to decline sequentially due to normal seasonality and third-quarter earnings to fall below second-quarter levels when stripping out the tariff refund benefit, with investment payoffs becoming more visible beginning in the fourth quarter. The quarter also marked the arrival of new CFO John Fortson and the resumption of share repurchases, with 1.3 million shares bought back at an average price below $10 per share for approximately $12 million.
Dentsply Sirona expands Medline Sinclair relationship to distribute technology portfolio across Canada
Dentsply Sirona announced an expansion of its long-standing relationship with Medline Sinclair, one of Canada's leading full-service dental distributors. Effective September 1, 2026, Medline Sinclair will begin offering Dentsply Sirona's technology portfolio across Canada, building on a relationship that previously focused on consumables. The expanded relationship increases access to Dentsply Sirona's digital dentistry solutions through Medline Sinclair's nationwide network of sales, service teams, and technical specialists. Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona, noted that this is the sixth dealer network enhancement announced in 2026, reflecting the company's commitment to strengthening commercial reach across North America. Peter Jugoon, SVP, Dental for Medline Sinclair, said Dentsply Sirona's technology portfolio aligns with the company's strategy to bring innovative solutions that enable customers to be more productive and profitable.
XRAY · Demand · Positive Expanded distribution of technology portfolio through Medline Sinclair increases access to digital dentistry solutions, likely boosting sales.
Dentsply Sirona sets August 6 conference call for second quarter results
Dentsply Sirona will host an investor conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time to review its second quarter 2026 financial results. Financial earnings materials will be posted on the Investors section of the company’s website prior to the call. A webcast replay will also be available after the call.
DENTSPLY SIRONA Shares Flat Since Cramer Called It a Value Play
DENTSPLY SIRONA shares have remained flat since Jim Cramer commented on the stock in early January. On January 6th, Cramer said on Mad Money that the dental products manufacturer used to be an expensive growth company and now represents some value, suggesting investors buy some and put it away. The stock is down 26.9% over the past year but up 3.4% year-to-date. After Cramer's remarks, the company reported fourth-quarter earnings on February 26th, posting $961 million in revenue and $0.27 in earnings per share, beating revenue estimates but missing on earnings; shares rose 15.5% the next day. On May 6th, shares fell 2% after first-quarter earnings showed a 39% annual drop in earnings per share.
Dental Consumables Market Size Expected to Reach USD 54.0 Billion by 2031
The global dental consumables market is projected to grow from USD 37.0 billion in 2026 to USD 54.0 billion by 2031, registering a CAGR of 7.9%. The increasing incidence of dental caries, periodontal diseases, and tooth loss is creating sustained demand for preventive, restorative, and therapeutic consumables. Dental restoration materials accounted for the largest product segment in 2025, driven by high volumes of restorative procedures such as fillings, crowns, and bridges. Dental hospitals and clinics represented the largest end-user segment due to their role as primary providers of dental care services. Asia Pacific is expected to register the highest growth rate, supported by rising healthcare expenditure, growing middle-class populations, and expanding dental tourism in countries like India, Thailand, and South Korea. Major companies include Institut Straumann AG, Envista, Dentsply Sirona, ZimVie Inc., and Solventum.
PDS Health surpasses five million CEREC chairside restorations with Dentsply Sirona
PDS Health and Dentsply Sirona announced that PDS Health practices have surpassed five million CEREC chairside restorations, marking a major milestone in scaled digital dentistry. The achievement reflects sustained clinician adoption across more than 1,200 CEREC systems installed in PDS Health practices nationwide. Founder and CEO Stephen E. Thorne IV said the milestone represents millions of patients receiving care without unnecessary delays or additional appointments. Dentsply Sirona Group Vice President, Americas Mark Bezjak called it a powerful example of sustained digital adoption at scale. The collaboration has enabled same-day restorative capabilities, greater efficiency, and a more connected patient experience.
XRAY · Demand · Positive PDS Health's milestone of 5M CEREC restorations demonstrates strong sustained demand for Dentsply Sirona's CEREC systems and consumables.
PDS Health (Pacific Dental Services) · Technology · Positive PDS Health achieved a major milestone in digital dentistry by surpassing 5M CEREC restorations, showcasing successful adoption of same-day restorative technology.
Dental Equipment Stocks Beat Q1 Revenue Estimates but Shares Decline
The four dental equipment and technology stocks tracked by StockStory reported strong first-quarter results, with aggregate revenues beating analysts' consensus estimates by 3% while next-quarter revenue guidance was in line. Dentsply Sirona posted flat revenue of $880 million, exceeding expectations by 4.8%, but its stock fell 10% since reporting. Envista delivered the fastest revenue growth among its peers at 14.4% to $705.5 million, yet shares declined 6.7%. Henry Schein, the weakest performer against estimates, saw revenue rise 6.3% to $3.37 billion and its stock gained 11.2%. Align Technology reported a 6.2% revenue increase to $1.04 billion, beating estimates, but its stock dropped 6.3%. On average, share prices across the group are down 2.9% since the latest earnings results.
USA